NBD AI Bulletin -- Betta Pharmaceuticals Co., Ltd. (the Company, SZ 300558, closing price: 109.4 yuan) announced on November 16 that it recently received a notice from Mr. FENLAI TAN over the progress of his share reduction plan, saying the aforementioned reduction plan has expired.

The Company's shareholder FENLAI TAN reduced 460,000 shares in the Company from May 18, 2020 to July 22, 2020, at 112.93 yuan each, accounting for 0.11% of the Company's total shares.

According to the Company's 2019 annual report, Betta Pharmaceuticals Co., Ltd. mainly engages in pharmaceutical manufacturing, accounting for 100.0% of its revenue.

Betta Pharmaceuticals Co., Ltd.'s chairman and general manager is Ding Lieming, male, 57 years old, Chinese national, no permanent residence abroad, Ph.D of the University of Arkansas.

Tips on "Stock Trends":

1. The number of shares held by northbound investors decreased by 2.0635 million in the past 30 days, accounting for 0.51% of the Company's circulating shares. 

2. One batch of organizations (53 in total) conducted researches on the Company in the past 30 days. 

3. The last shareholding reduction announcement of Betta Pharmaceuticals Co., Ltd. was issued on October 22, 2020, and its share price fell 3.46% on the following trading day. The Company issued a total of 19 such announcements in the past 12 months.

(By Tan Yuhan)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.